Type 1 Diabetes

Adolescents and young adults with type 1 diabetes who used a next-generation hybrid closed-loop insulin delivery system saw improvements in HbA1c and time-in-range with no increase in hypoglycemia, study data show.

One approach to improve care and clinical outcomes for people with type 1 diabetes involves the use of adjunctive therapies along with insulin to improve glucose control or enable reductions in insulin doses.

A small study of young children with type 1 diabetes and their parents suggests that continuous glucose monitoring technology may improve a child’s sleep by minimizing wake periods during the night for blood glucose monitoring, whereas a parent’s sleep may be more disrupted by frequent nighttime blood glucose checks when using CGM, according to findings published in Diabetes Technology & Therapeutics.

I derive great energy and enthusiasm from my patients; my patients have always inspired me to strive to be a better doctor.

More than 100,000 children and adults with type 1 diabetes using a hybrid closed-loop insulin delivery system maintained a blood glucose level in the recommended range 71.3% of the time and experienced an improvement in time in range when using the device in automode, according to a real-world analysis accepted for presentation at the Endocrine Society Annual Meeting.

The FDA on Friday issued a complete response letter for a supplemental new drug application for a 2.5 mg dose of the SGLT2 inhibitor empagliflozin as an adjunct to insulin for adults with type 1 diabetes, according to a press release from Boehringer Ingelheim and Eli Lilly.

Clear phenotypic differences can be detected in the pancreases of children with type 1 diabetes when stratified by age at diagnosis, according to findings published in Diabetologia.

Adults with type 1 diabetes on multiple daily injection therapy saw no benefit in glycemic measures when adding on preprandial injections of short-acting exenatide, according to findings from a phase 2a study published in The Lancet Diabetes & Endocrinology.

Chinese adults with type 1 diabetes can avoid insulin-related weight gain and use less insulin by adding metformin to treatment regimens, according to findings published in the Journal of Diabetes.

Adults with type 2 diabetes who lost enough weight to enter diabetes remission were also able to achieve normal beta-cell function. It was the top story in endocrinology last week.